A Phase II Study of MGCD0103 (MG-0103) in Patients With Relapsed or Refractory Hodgkin's Lymphoma.

Trial Profile

A Phase II Study of MGCD0103 (MG-0103) in Patients With Relapsed or Refractory Hodgkin's Lymphoma.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 08 Jul 2015

At a glance

  • Drugs Mocetinostat (Primary)
  • Indications Hodgkin's disease
  • Focus Therapeutic Use
  • Sponsors Mirati Therapeutics
  • Most Recent Events

    • 28 Apr 2011 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 08 Dec 2010 Status changed from suspended to completed.
    • 07 Dec 2010 Results will be reported at ASH 2010, according to a MethylGene media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top